The acute pancreatitis market size is expected to reach US$ 8,827.37 million by 2030 from US$ 5,649.77 million in 2022; it is estimated to record a CAGR of 5.7% from 2022 to 2030.
The pancreas produces insulin, a hormone that regulates blood sugar levels. Pancreatitis can harm insulin-producing cells of pancreas, which causes diabetes in patients suffering from acute pancreatitis. People suffering from acute pancreatitis are at a twofold greater risk of diabetes as compared to the general population. The World Health Organization (WHO) American Diabetes Association has classified the development of diabetes after acute pancreatitis as exocrine pancreatic diabetes (pancreatogenic diabetes). Pancreatogenic diabetes is increasingly being linked to exocrine disorders of the pancreas. Diabetes sequelae are observed across the spectrum of severity in acute pancreatitis and can accompany other clinical complications.
As per the European Review for Medical and Pharmacological Sciences, published in 2022, the prevalence of pancreatogenic diabetes is 5-10% in the Western diabetic population, and chronic pancreatitis is responsible for 20% of cases while acute pancreatitis causes 80% of cases. According to an article published in the National Library of Medicine in 2021, ~23% of acute pancreatitis patients are likely to develop diabetes within three years of discharge. Further, an article published in the Journal of Gastroenterology in 2020 states that following acute pancreatitis, ~3%, 7%, 9%, and 11% of patients develop diabetes at 6, 12, 18, and 24 months of discharge, respectively. According to an article published in the MDPI, in 2023, ~40% of patients with acute pancreatitis are affected by prediabetes and diabetes, and are at a higher risk of death and readmission to hospitals than patients with type 2 diabetes. Further, ~ 60.2% of adult patients developed diabetes after acute pancreatitis, and 9% of children after acute recurrent pancreatitis or with chronic pancreatitis, and this risk increases as they age into adulthood. Researchers have noted higher diabetes incidence (~39%) after severe acute pancreatitis than mild acute pancreatitis (14%) in a meta-analysis comparing severe and mild acute pancreatitis.
A Chinese research study suggests that hypertriglyceridemia (HTG) has outpaced alcohol to become the second leading cause of acute pancreatitis. Approximately 29% of patients experience repeated episodes that result in recurrent acute pancreatitis (RAP) and 44.6% of these patients had HTG as an etiological condition. In an article published in Biomed Central in June 2023, HTG has been stated as a significant independent risk factor for the severity and recurrence of acute pancreatitis. Thus, the increasing incidence of diabetes in patients suffering or recovering from acute pancreatitis contributes to the growth of the acute pancreatitis market.
The acute pancreatitis market is segments into product and end user. Based on offerings, the Acute Pancreatitis Market is segmented into medication, diagnosis, and others. In 2022, the diagnosis segment held the largest share of the market. Moreover, the others segment is expected to record the fastest CAGR during the forecast period (2022-2030). The acute pancreatitis market for the diagnosis segment is further segmented into blood tests, CT scans, stool tests, ultrasound, MRI, and urine tests. Based on causes, the acute pancreatitis market is classified into gallstones, alcoholism, genetic disorders, infection, and others. In 2022, the gallstones segment held the largest share of the market. The same segment is expected to record the highest CAGR rate during the forecast period (2022-2030). Based on end user, the acute pancreatitis market is classified into hospitals, diagnostic laboratories, ambulatory surgical centers, and others. In 2022, the hospitals segment held the largest share of the market. The acute pancreatitis market for the diagnostic laboratories segment is estimated to grow at a CAGR of 6.4% during the forecast period (2022-2030).
Based on geopgraphy, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The North America fregion held the largest market share of the acute pancreatitis market. The acute pancreatitis market in North America is expected to grow due to the increasing burden of the disease with an increase in the number of gallstone cases and excessive consumption of alcohol. Also, technological advancements in healthcare facilities are benefitting the acute pancreatitis market in North America. The US reports an increasingly large number of acute pancreatitis cases due to a wide-scale practice of alcohol consumption and an upsurge in the cases of gallstones. APAC is expected to register the highest growth rate during 2022-2030. The market growth in APAC is attributed to factors including rising cases of pancreatitis, researchers to develop a treatment for pancreatitis, and government efforts to raise awareness among the population. In addition, alcohol-related pancreatitis cases also fuels the growth of the market in the region.
The Organisation for Economic Co-operation and Development (OECD), Centers for Disease Control and Prevention (CDC), European Union, and National Institutes of Health (NIH) are a few key primary and secondary sources referred to while preparing the report on the acute pancreatitis market.
Reasons to Buy
The pancreas produces insulin, a hormone that regulates blood sugar levels. Pancreatitis can harm insulin-producing cells of pancreas, which causes diabetes in patients suffering from acute pancreatitis. People suffering from acute pancreatitis are at a twofold greater risk of diabetes as compared to the general population. The World Health Organization (WHO) American Diabetes Association has classified the development of diabetes after acute pancreatitis as exocrine pancreatic diabetes (pancreatogenic diabetes). Pancreatogenic diabetes is increasingly being linked to exocrine disorders of the pancreas. Diabetes sequelae are observed across the spectrum of severity in acute pancreatitis and can accompany other clinical complications.
As per the European Review for Medical and Pharmacological Sciences, published in 2022, the prevalence of pancreatogenic diabetes is 5-10% in the Western diabetic population, and chronic pancreatitis is responsible for 20% of cases while acute pancreatitis causes 80% of cases. According to an article published in the National Library of Medicine in 2021, ~23% of acute pancreatitis patients are likely to develop diabetes within three years of discharge. Further, an article published in the Journal of Gastroenterology in 2020 states that following acute pancreatitis, ~3%, 7%, 9%, and 11% of patients develop diabetes at 6, 12, 18, and 24 months of discharge, respectively. According to an article published in the MDPI, in 2023, ~40% of patients with acute pancreatitis are affected by prediabetes and diabetes, and are at a higher risk of death and readmission to hospitals than patients with type 2 diabetes. Further, ~ 60.2% of adult patients developed diabetes after acute pancreatitis, and 9% of children after acute recurrent pancreatitis or with chronic pancreatitis, and this risk increases as they age into adulthood. Researchers have noted higher diabetes incidence (~39%) after severe acute pancreatitis than mild acute pancreatitis (14%) in a meta-analysis comparing severe and mild acute pancreatitis.
A Chinese research study suggests that hypertriglyceridemia (HTG) has outpaced alcohol to become the second leading cause of acute pancreatitis. Approximately 29% of patients experience repeated episodes that result in recurrent acute pancreatitis (RAP) and 44.6% of these patients had HTG as an etiological condition. In an article published in Biomed Central in June 2023, HTG has been stated as a significant independent risk factor for the severity and recurrence of acute pancreatitis. Thus, the increasing incidence of diabetes in patients suffering or recovering from acute pancreatitis contributes to the growth of the acute pancreatitis market.
The acute pancreatitis market is segments into product and end user. Based on offerings, the Acute Pancreatitis Market is segmented into medication, diagnosis, and others. In 2022, the diagnosis segment held the largest share of the market. Moreover, the others segment is expected to record the fastest CAGR during the forecast period (2022-2030). The acute pancreatitis market for the diagnosis segment is further segmented into blood tests, CT scans, stool tests, ultrasound, MRI, and urine tests. Based on causes, the acute pancreatitis market is classified into gallstones, alcoholism, genetic disorders, infection, and others. In 2022, the gallstones segment held the largest share of the market. The same segment is expected to record the highest CAGR rate during the forecast period (2022-2030). Based on end user, the acute pancreatitis market is classified into hospitals, diagnostic laboratories, ambulatory surgical centers, and others. In 2022, the hospitals segment held the largest share of the market. The acute pancreatitis market for the diagnostic laboratories segment is estimated to grow at a CAGR of 6.4% during the forecast period (2022-2030).
Based on geopgraphy, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The North America fregion held the largest market share of the acute pancreatitis market. The acute pancreatitis market in North America is expected to grow due to the increasing burden of the disease with an increase in the number of gallstone cases and excessive consumption of alcohol. Also, technological advancements in healthcare facilities are benefitting the acute pancreatitis market in North America. The US reports an increasingly large number of acute pancreatitis cases due to a wide-scale practice of alcohol consumption and an upsurge in the cases of gallstones. APAC is expected to register the highest growth rate during 2022-2030. The market growth in APAC is attributed to factors including rising cases of pancreatitis, researchers to develop a treatment for pancreatitis, and government efforts to raise awareness among the population. In addition, alcohol-related pancreatitis cases also fuels the growth of the market in the region.
The Organisation for Economic Co-operation and Development (OECD), Centers for Disease Control and Prevention (CDC), European Union, and National Institutes of Health (NIH) are a few key primary and secondary sources referred to while preparing the report on the acute pancreatitis market.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the acute pancreatitis market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global acute pancreatitis market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the acute pancreatitis market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Acute Pancreatitis Market Landscape
5. Acute Pancreatitis Market - Key Industry Dynamics
6. Acute Pancreatitis Market - Global Market Analysis
7. Global Acute Pancreatitis Market - Revenue and Forecast to 2030 - by Offerings
8. Global Acute Pancreatitis Market - Revenue and Forecast to 2030 - by Causes
9. Global Acute Pancreatitis Market - Revenue and Forecast to 2030 - by End User
10. Acute Pancreatitis Market - Geographical Analysis
11. Acute Pancreatitis Market-Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned
- Abbott Laboratories
- GE HealthCare Technologies Inc
- Samsung Healthcare
- Koninklijke Philips NV
- Baxter International Inc
- Dynavax Technologies Corp
- Actim Oy
- Medtronic Plc
- Boston Scientific Corp
- Fresenius Kabi AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 196 |
| Published | September 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 5.65 Billion |
| Forecasted Market Value ( USD | $ 8.83 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
